Literature DB >> 1339195

Oliver memorial lecture. Towards the conquest of Rh haemolytic disease: Britain's contribution and the role of serendipity.

L A Tovey1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1339195     DOI: 10.1111/j.1365-3148.1992.tb00142.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


× No keyword cloud information.
  7 in total

1.  Forty years of anti-D immunoprophylaxis.

Authors:  Giorgio Reali
Journal:  Blood Transfus       Date:  2007-01       Impact factor: 3.443

2.  Survey on the prevention and incidence of haemolytic disease of the newborn in Italy.

Authors:  Francesco Bennardello; Giuseppe Curciarello
Journal:  Blood Transfus       Date:  2013-06-14       Impact factor: 3.443

3.  Reaction to anti-D immunoglobulin - can we manage it?

Authors:  Katherine O'Brien; Dimitrios Siassakos; Janet Birchall; Mark Gompels; Sarah Allford; Ken Bidgood
Journal:  Obstet Med       Date:  2009-03-01

4.  The prevalence of maternal F cells in a pregnant population and potential overestimation of foeto-maternal haemorrhage as a consequence.

Authors:  Deirdre Corcoran; Deirdre Murphy; Jennifer C Donnelly; Fionnuala Ni Ainle
Journal:  Blood Transfus       Date:  2013-06-12       Impact factor: 3.443

5.  Rh isoimmunization in Sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies.

Authors:  Erhabor Osaro; Adias Teddy Charles
Journal:  Int J Womens Health       Date:  2010-12-01

6.  Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis.

Authors:  Xiaohui Xie; Qiurong Fu; Ziwei Bao; Yi Zhang; Dan Zhou
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

7.  Trophoblast antigens, fetal blood cell antigens, and the paradox of fetomaternal tolerance.

Authors:  Gabrielle Rizzuto; Adrian Erlebacher
Journal:  J Exp Med       Date:  2022-04-13       Impact factor: 17.579

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.